Comparison between incidentally and clinically detected prostate cancer: Implications for prostate cancer screening programs and focal therapy

Analytical and Quantitative Cytology and Histology

Volumn 32, Issue 3, 2010, Pages 151-154

  Mazzucchelli, Roberta ^a   Montironi, Rodolfo ^a   Morichetti, Doriana ^a   Scarpelli, Marina ^a   Lopez Beltran, Antonio ^b   Cheng, Liang ^c  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical cancer; Incidental cancer; Prostate cancer; Prostate, early detection and screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYSTECTOMY; HUMAN; INCIDENTAL FINDING; MORBIDITY; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR VOLUME;

CYSTECTOMY; EARLY DETECTION OF CANCER; HUMANS; INCIDENTAL FINDINGS; MALE; MASS SCREENING; PROSTATECTOMY; PROSTATIC NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 77953031816     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Mazzucchelli R, Barbisan F, Scarpelli M, Lopez-Beltran A, van der Kwast TH, Cheng L, Montironi R: Is incidentally detected prostate cancer in patients undergoing radical cystoprostatectomy clinically significant? Am J Clin Pathol 2009; 131:279-283
2. Barbisan F, Mazzucchelli R, Santinelli A, Lopez-Beltran A, Cheng L, Scarpelli M, Montorsi F, Montironi R: Overexpression of ELAV-like protein HuR is associated with increased COX-2 expression in atrophy, high-grade prostatic intraepithelial neoplasia, and incidental prostate cancer in cystoprostatectomies. Eur Urol 2009;56:105-112
3. Moutzouris G, Barbatis C, Plastiras D, Mertziotis N, Katsifotis C, Presvelos V, Theodorou C: Incidence and histological findings of unsuspected prostatic adenocarcinoma in radical cystoprostatectomy for transitional cell carcinoma of the bladder. Scand J Urol Nephrol 1999;33:27-30 (Pubitemid 29359280)
4. Delongchamps NB, Mao K, Theng H, Zerbib M, Debré B, Peyromaure M: Outcome of patients with fortuitous prostate cancer after radical cystoprostatectomy for bladder cancer. Eur Urol 2005;48:946-950 (Pubitemid 41641641)
5. Prange W, Erbersdobler A, Hammerer P, Graefen M, Hautmann SH, Hautmann RE, Huland H, Henke RP: High-grade prostatic intraepithelial neoplasia in cystoprostatectomy specimens. Eur Urol 2001;39:30-31 (Pubitemid 32429652)
6. Abbas F, Hochberg D, Civantos F, Soloway M: Incidental prostatic adenocarcinoma in patients undergoing radical cystoprostatectomy for bladder cancer. Eur Urol 1996;30: 322-326 (Pubitemid 26362873)
7. Postma R, Schröder FH, van Leenders GJ, Hoedemaeker RF, Vis AN, Roobol MJ, van der Kwast TH: Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Section Rotterdam: A comparison of two rounds of screening. Eur Urol 2007;52: 89-97 (Pubitemid 46803013)
8. Polascik TJ, Mayes JM, Sun L, Madden JF, Moul JW, Mouraviev V: Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: Implications for unilateral ablative therapy. Prostate 2008;68:1380-1386
9. Cheng L, Poulos CK, Pan CX, Jones TD, Daggy JK, Eble JN, Koch MO: Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens. J Urol 2005;174:898-902 (Pubitemid 41140625)
10. Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ: Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 2007;110:906-910 (Pubitemid 47257670)